Dr Marc Kamin joins PharmaNet
This article was originally published in Scrip
PharmaNet Development Group (US), a provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, has named Dr Marc Kamin vice-president of medical and scientific affairs, neuroscience. Dr Kamin, who has 20 years' experience in the pharmaceutical industry, most recently worked at Johnson & Johnson, where he led the central trial co-ordination group for medical affairs in global clinical operations.
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.